All products are for laboratory research use only. Not for human consumption.
Longevity · Longevity Neuroprotection
The Cellular Powerhouse
RM 460
Ignite your cellular fuel. NAD+ 1000 mg replenishes your body’s vital longevity molecule, turning back the clock on depleted energy from the inside out.
For research use only. Not for human or veterinary consumption. This product is not a medicine and is not intended to diagnose, treat, cure or prevent any disease.
Overview
NAD+ is the obligate cofactor for all 7 sirtuins, PARP-1 DNA repair, and 500+ enzymatic reactions. By age 60, circulating NAD+ has declined 50% from youthful levels. This preparation achieves pharmaceutical parenteral standards with endotoxin control below 1 EU/mg, LAL-tested per batch — critical for research where endotoxin-driven inflammatory confounding must be eliminated.
Mechanism of action
All 7 sirtuins require NAD+ as obligate cofactor — none function without it
Poly(ADP-ribose) polymerase — first responder to DNA damage
NAD+/NADH ratio is the critical variable in oxidative phosphorylation
Key finding NAD+ declines 50% between ages 40 and 60, rendering 7 sirtuins — the primary longevity enzymes — partially or fully inactive. Restoring NAD+ to youthful levels directly reactivates all 7 sirtuins simultaneously, something no other single intervention can achieve.
Key research findings
Decline in circulating NAD+ between young adulthood and age 60 in human plasma measurements
Verdin E. Science, 2015All 7 sirtuins require NAD+ as obligate cofactor — activity directly proportional to NAD+ availability
Guarente L. Cell, 2013Primary DNA repair enzyme — consumes NAD+ as substrate; competes with sirtuins at low NAD+ levels
Bai P et al. Cell Metab, 2011NAD+ precursors restore youthful NAD+ levels in animal aging models with significant lifespan extension
Mills KF et al. Cell Metab, 2016Research areas
NAD+ decline is mechanistically central to aging — restoring it is the most direct longevity intervention identified.
PARP-1 consumes NAD+ as its primary substrate — NAD+ availability directly governs DNA repair capacity.
NAD+/NADH ratio governs mitochondrial efficiency — NAD+ restoration reverses age-related ETC dysfunction.
NAD+ restoration improves insulin sensitivity, metabolic rate, and lipid metabolism across multiple disease models.
Safety profile
NAD+ is an endogenous molecule with well-established safety. The primary research consideration is ensuring adequate endotoxin control for parenteral applications — which this preparation meets.
This preparation: <1 EU/mg LAL-tested. Standard NAD+ may not meet this threshold — critical for parenteral research
NAD+ degrades rapidly in aqueous solution — use within 24 hours of reconstitution
At normal NAD+ levels, PARP and sirtuins compete. Research designs should account for this dynamic
Rapid IV administration of high NAD+ doses can cause transient flushing — dose-rate dependent
Molecular profile
Frequently asked questions
Endotoxins (bacterial lipopolysaccharides) cause significant inflammatory reactions that confound research results by activating NF-kB, releasing inflammatory cytokines, and altering the very pathways NAD+ is intended to study. Standard NAD+ preparations may not control endotoxin levels. This preparation meets pharmaceutical parenteral standards (<1 EU/mg, LAL-tested), ensuring inflammatory confounding is eliminated.
NAD+ undergoes hydrolytic degradation in aqueous solution — the N-glycosidic bond between nicotinamide and ribose hydrolyzes under physiological pH and temperature conditions. This is a fundamental chemical property, not a formulation deficiency. Lyophilized powder is stable for 24 months; reconstituted solution should be used within 24 hours.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors that the body converts to NAD+. Direct NAD+ bypasses the biosynthetic steps but has poorer cell membrane permeability (it cannot cross cell membranes easily and must be converted extracellularly or taken up by specific transporters). For research requiring precise intracellular NAD+ delivery, precursors may be preferable; for extracellular or plasma NAD+ research, direct NAD+ is appropriate.
NAD+ is the essential cofactor for sirtuins — the primary enzymes governing DNA repair, metabolic regulation, stress resistance, and longevity. As NAD+ declines 50% by age 60, sirtuin activity falls proportionally, reducing DNA repair capacity, mitochondrial efficiency, and metabolic flexibility. Simultaneously, chronic DNA damage forces PARP-1 to consume remaining NAD+ for repair, further reducing sirtuin availability — a self-amplifying decline that NAD+ restoration can interrupt.
Both PARP-1 (DNA repair) and sirtuins (longevity signaling) require NAD+ as their primary substrate. When NAD+ levels fall with age, these enzymes effectively compete for scarce cofactor. PARP-1 has higher affinity at DNA damage sites, so DNA repair gets prioritized — but at the cost of sirtuin activity and all the longevity signaling they provide. Restoring NAD+ to youthful levels allows both to function simultaneously.
NAD+ (and its reduced form NADH) serve as electron carriers in metabolic processes across all major biochemical pathways: glycolysis, the citric acid cycle, oxidative phosphorylation, fatty acid oxidation, and amino acid metabolism. Additionally, NAD+ is consumed as substrate by sirtuins and PARPs. The 500+ figure refers to distinct enzymatic reactions in which NAD+/NADH participates as a cofactor or substrate.
References
